Brexit: UK pharma fears international IP exhaustion scheme
Pharma in-house counsel say an international IP exhaustion framework could undercut the UK drugs market and create shortages in other parts of the world
A post-Brexit international IP exhaustion scheme could create drug shortages and profit losses for pharmaceutical businesses, according to industry in-house sources in the UK.
As a former EU member state, the UK historically benefited from parallel imports of...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.